Evotec has filed a patent for novel interferon-associated antigen binding proteins that effectively disrupt viral replication and reduce HBV viral load. The invention also includes nucleic acids, vectors, and vector systems encoding these proteins, as well as compositions for medical use in treating hepatitis B virus (HBV) infection. The patent also covers host cells and methods for producing these proteins. GlobalData’s report on Evotec gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Evotec SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Evotec, NSAID cancer drugs was a key innovation area identified from patents. Evotec's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Novel interferon-associated antigen binding proteins for treating hbv infection

Source: United States Patent and Trademark Office (USPTO). Credit: Evotec SE

A recently filed patent (Publication Number: US20230279137A1) describes a composition for treating hepatitis B virus (HBV) infection and reducing associated symptoms. The composition includes an interferon-associated antigen binding protein, which consists of an agonistic anti-CD40 antibody or its antigen binding fragment, and Interferon-a2a (IFNa2a) or a functional fragment of it. The agonistic anti-CD40 antibody or its fragment is composed of a heavy chain and a light chain, each with specific amino acid sequences. The heavy chain includes complementarity determining regions (CDRH1, CDRH2, and CDRH3) with specific amino acid sequences, while the light chain includes complementarity determining regions (CDRL1, CDRL2, and CDRL3) with specific amino acid sequences.

The composition can also include a fusion of IFNa2a or its functional fragment to either the light chain or the heavy chain of the agonistic anti-CD40 antibody or its fragment. The fusion can occur at the C-terminus of the respective chain. Additionally, a linker can be used to connect the agonistic anti-CD40 antibody or its fragment to IFNa2a or its fragment. The linker can have specific amino acid sequences.

The patent also describes methods for treating HBV infection and reducing associated symptoms using the pharmaceutical composition mentioned above. The methods involve administering an effective amount of the composition to a subject. The symptoms of HBV infection can include chronic inflammation of the liver, hepatocellular carcinoma, membranous glomerulonephritis, risk of death, acute necrotizing vasculitis, papular acrodermatitis of childhood, HBV-associated nephropathy, and immune-mediated hematological disorders. In the case of acute viral hepatitis, symptoms such as loss of appetite, nausea, vomiting, body aches, dark urine, jaundice, fulminant hepatic failure, low-grade fever, stomach pain, and bloated stomach can be targeted.

The patent also covers the use of nucleic acids, vectors, vector systems, and isolated host cells encoding the interferon-associated antigen binding protein. These components can be used for the production and delivery of the composition for treating HBV infection and reducing associated symptoms.

In summary, the patent describes a composition and methods for treating HBV infection and reducing associated symptoms using an interferon-associated antigen binding protein. The composition includes an agonistic anti-CD40 antibody or its fragment, and IFNa2a or its fragment, with specific amino acid sequences and fusion configurations. The patent also covers the use of nucleic acids, vectors, vector systems, and isolated host cells for the production and delivery of the composition.

To know more about GlobalData’s detailed insights on Evotec, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies